Physician profile
Robert Dougherty
NPI 1386326395
$4,273.39
in general payments reported to CMS, 2019-2025
17 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $288 · 2024: $1,471 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,168.62 |
| Education | $104.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $941.68 | 2023-2025 | Rocklatan, Precision7, Rhopressa |
| Bausch & Lomb Americas INC. | $608.08 | 2023-2025 | Miebo, Infuse, Biotrue |
| Mallinckrodt Hospital Products INC. | $568.38 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $328.85 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $324.91 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $261.73 | 2024-2025 | |
| Oyster Point Pharma, INC. | $197.20 | 2023-2024 | Tyrvaya |
| Abbvie INC. | $156.03 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $155.86 | 2024 | Syfovre |
| Merz North America, INC. | $143.21 | 2025 | |
| Glaukos Corporation | $130.88 | 2025 | Idosetr, Istent Inject W, Istent Infinite |
| Rxsight INC | $127.90 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Lkc Technologies, INC. | $121.13 | 2025 | |
| Coopervision INC. | $118.86 | 2025 | Misight Contact Lens |
| Biotissue Holdings INC. | $48.37 | 2024-2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $22.22 | 2025 | Dextenza |
| Thea Pharma INC. | $18.10 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.